• 生物活性

靶点及简介 ：

A IgG4-kappa monoclonal antibody against PD-1

Pembrolizumab 是一种人源化抗体，为 PD-1 的抑制剂，用于癌症免疫的研究。

Pembrolizumab 派姆单抗是一种有效的、高选择性的、人源IgG4-kappa单克隆抗体，同时也是抑制剂，靶向PD-1，具有潜在的免疫检查点抑制活性和抗肿瘤活性。PD-1 与派姆单抗的结合位于 PD-1 的 C'D 环上。MW：146.286 KD。

除了黑素瘤和肺癌，pembrolizumab在其他晚期实体肿瘤和恶性血液病中同样也具有疗效。Pembrolizumab具有在可接受范围的副作用，在具有晚期非小细胞肺癌的患者中，具有抗肿瘤活性

• 验证及参考文献

验证：

参考文献：

[1] Minan Wang, et al. FASEB J. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy

[2] Shuguang Tan, et al. Nat Commun. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

[3] Reck M, et al. N Engl J Med. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

[4] Faghfuri E, et al. Expert Rev Anticancer Ther. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.

[5] Barbee MS, et al. Ann Pharmacother. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.

[6] Garon EB, et al. N Engl J Med. Pembrolizumab for the treatment of non-small-cell lung cancer.

[7]. Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017 Aug 16. pii: S0140-6736(17)31601-X.